eXoZymes, Inc.
EXOZHealthcare|Biotechnology|US
$4.40
+0.29 (+7.06%)
DCF Value
$0.14
Tangible Book / Share
$0.42
Cash / Share
$0.65
About
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Stock Price
-67.4%(1Y)
1M
-16.5%
3M
-13.9%
6M
-54.3%
YTD
-59.6%
1Y
-72.5%
3Y
-49.1%
5Y
-49.1%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$40.8M
Employees3,000 (+0% YoY)
CEOMichael Heltzen
IPO DateNov 13, 2024
Beta3.35
52-Week Range$3.24 – $18.4
Avg Volume9,177
ExchangeNASDAQ
Websiteexozymes.com
Ownership
Float26.7%
Shares Outstanding9.3M
Recent Insider Trades
Perriman Damien AlanOPTION EX.
Oct 9, 20263,922 shares
Perriman Damien AlanOPTION EX.
Oct 9, 20263,922 shares
Perriman Damien AlanSELL
Oct 12, 20263,729 shares @ $5.21
Korman Tyler PazOTHER
Aug 19, 20260 shares
Rayo Edgardo JavierAWARD
Oct 1, 202625,000 shares @ $6.28
Peers
Recent News
eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research
Oct 21, 2026 · accessnewswire.com
Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"
Oct 2, 2026 · thenewswire.com
Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)
Sep 17, 2026 · defenseworld.net
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
Sep 8, 2026 · accessnewswire.com
eXoZymes Q2 Earnings Call Highlights
Aug 22, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:10 AM